Session Abstract – PMWC 2020 Silicon Valley


A growing body of evidence suggests that the broader community of gut microbes may influence cancer risk, provide diagnostic insight, shape clinical course, and impact treatment success. Microbiome-directed therapies hold tremendous promise for personalized therapies and improved treatment outcomes.

 Session Chair Profile

M.D., Ph.D., Head of the Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center

Biography
Marcel van den Brink is a medical oncologist with experience in both laboratory and clinical research, particularly in strategies to improve allogeneic bone marrow transplantation (BMT). He is the Head of the Division of Hematologic Malignancies at MSKCC and holds a joint appointment in the Immunology and Transplantation Program. As a clinical scientist he has been involved in immunotherapeutic trials of cytokines, cell therapies, tumor vaccines and BMT for patients with hematologic malignancies. His laboratory is devoted to the immunology of BMT and he studies post-transplant immune reconstitution, pathophysiology of graft-versus-host disease, the intestinal microbiota in BMT recipients, and the biology of graft-versus-tumor in patients and mouse models. Both as a Division Head and a laboratory Principal.

Talk
Impact Of Microbiota On Allogeneic HCT
Patients undergoing HCT display dramatic changes in composition of their intestinal flora during Allogeneic HCT. These changes can lead to or have significant impact on clinically relevant outcomes including relapse, GVHD, infections, and organ toxicity. Manipulation of intestinal flora offers a novel approach to improve overall outcomes after Allo HCT.


 Speaker Profile

M.D., Chief Medical Officer, Seres Therapeutics

Biography
Kevin Horgan has worked extensively on therapeutics and diagnostics in inflammation and oncology, across both early and late stage development. Most recently he led the development of combination immunotherapies in oncology at Astra Zeneca, prior to joining Seres Therapeutics in October 2018. Seres develops microbiome based therapeutics for infection, inflammatory diseases and cancer. He graduated in medicine from University College Cork in 1982. He completed postgraduate medical training at the Johns Hopkins Hospital in Baltimore, MD, the National Cancer Institute in Bethesda, MD, and UCLA in internal medicine, immunology and gastroenterology. At Merck Research Laboratories, he led the development of Emend® for the prevention of nausea and vomiting associated with cancer chemotherapy.

Talk
Leveraging The Gastrointestinal Microbiome For Clinical Benefit
Awareness of the gastrointestinal microbiome as an important determinant of health has recently increased. I will outline an approach for the development of microbiome based therapies that has led to encouraging clinical data in the treatment of ulcerative colitis and optimism for the future of this novel modality in a broad spectrum of settings.